{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:58:23Z","timestamp":1780984703237,"version":"3.54.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.ARUMS.REC.1401.173"],"award-info":[{"award-number":["IR.ARUMS.REC.1401.173"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejmech.2024.116396","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T09:59:25Z","timestamp":1713261565000},"page":"116396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships"],"prefix":"10.1016","volume":"271","author":[{"given":"J.","family":"Abbasi Shiran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kaboudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-2497","authenticated-orcid":false,"given":"N.","family":"Razzaghi-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116396_bib1","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/puh2.100","article-title":"Enhancing communication strategies in controlling neglected tropical diseases in Nigeria","volume":"2","author":"Durojaye","year":"2023","journal-title":"Public Health Chall"},{"key":"10.1016\/j.ejmech.2024.116396_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-018-0327-4","article-title":"Challenges and recent progress in drug discovery for tropical diseases","volume":"559","author":"De Rycker","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116396_bib3","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2022.0272","article-title":"Introduction to the special issue: challenges and opportunities in the fight against neglected tropical diseases: a decade from the London Declaration on NTDs","volume":"378","author":"Forbes","year":"2023","journal-title":"Phil Trans R Soc B"},{"key":"10.1016\/j.ejmech.2024.116396_bib4","unstructured":"World Health Organization. Leishmaniasis, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis (accessed in October 2022).."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008248","article-title":"Investigating barriers and challenges to the integrated management of neglected tropical skin diseases in an endemic setting in Nigeria","volume":"14","author":"Ukwaja","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib6","unstructured":"https:\/\/www.who.int\/teams\/control-of-neglected-tropical-diseases\/global-report-on-neglected-tropical-diseases-2023 (accessed 18 September 2023)."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116396_bib7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.drudis.2022.04.004","article-title":"Approaches to advance drug discovery for neglected tropical diseases","volume":"27","author":"Ferreira","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116396_bib8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1590\/0037-8682-0415-2016","article-title":"High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala","volume":"49","author":"Brum-Soares","year":"2016","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.ejmech.2024.116396_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2019.100507","article-title":"Chagas disease: chronic chagas cardiomyopathy","volume":"46","author":"Echavarr\u00eda","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejmech.2024.116396_bib10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3389\/fmicb.2018.02655","article-title":"Host-directed drug therapies for neglected tropical diseases caused by protozoan parasites","volume":"9","author":"Varikuti","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116396_bib11","first-page":"35","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"21","author":"De Rycker","year":"2023","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ejmech.2024.116396_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106518","article-title":"Current status and structure activity relationship of privileged azoles as antifungal agents","volume":"59","author":"Ahmadi","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2024.116396_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2024.116396_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116396_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00583-22","article-title":"Antileishmanial activities of (Z)-2-(nitroimidazolylmethylene)-3(2H)-benzofuranones: synthesis, in vitro assessment, and bioactivation by NTR 1 and 2","volume":"66","author":"Navidpour","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116396_bib16","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.drudis.2022.04.004","article-title":"Approaches to advance drug discovery for neglected tropical diseases","volume":"27","author":"Ferreira","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.jmedchem.2c00775","article-title":"Collaborative virtual screening identifies a 2-aryl-4-aminoquinazoline series with efficacy in an in vivo model of trypanosoma cruzi infection","volume":"66","author":"Tawaraishi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.614073","article-title":"Use of artificial intelligence and machine learning for discovery of drugs for neglected tropical diseases","volume":"9","author":"Winkler","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2174\/156802661708170126200430","article-title":"Editorial: hybrid compounds as multitarget agents in medicinal chemistry-part I","volume":"17","author":"Scotti","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116396_bib20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/cmdc.201900165","article-title":"Synthesis and evaluation of new nifurtimox-adamantane adducts with trypanocidal activity","volume":"14","author":"Foscolos","year":"2019","journal-title":"ChemMedChem"},{"issue":"15","key":"10.1016\/j.ejmech.2024.116396_bib21","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.bmcl.2017.05.071","article-title":"Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum","volume":"27","author":"Col\u00edn-Lozano","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116396_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2018.05.014","article-title":"Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents","volume":"154","author":"Upadhyay","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib23","doi-asserted-by":"crossref","first-page":"34008","DOI":"10.1021\/acsomega.3c04878","article-title":"Development of new leishmanicidal compounds via bioconjugation of antimicrobial peptides and antileishmanial guanidines","volume":"8","author":"Costa","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116396_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"van Griensven","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib25","first-page":"4","article-title":"Compressing the timelines for development and delivery: Accelerating access to triple-drug therapy to eliminate lymphatic filariasis","volume":"106","author":"Jacobson","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib26","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.actatropica.2013.11.003","article-title":"Combination therapy with nitazoxanide and amphotericin B, Glucantime, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes","volume":"130","author":"Mesquita","year":"2014","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2024.116396_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1590\/S0103-50532001000300003","article-title":"Trypanocidal activity of isolated naphthoquinones from Tabebuia and some heterocyclic derivatives: a review from an interdisciplinary study","volume":"12","author":"De Moura","year":"2001","journal-title":"J. Braz. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14656566.2013.755515","article-title":"Leishmaniasis: an update of current pharmacotherapy","volume":"14","author":"Sundar","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib31","article-title":"What constitutes a neglected tropical disease?","volume":"14","author":"Hotez","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib33","first-page":"5","article-title":"Childhood Mediterranean visceral leishmaniasis","volume":"11","author":"Cascio","year":"2003","journal-title":"Inf. Med."},{"key":"10.1016\/j.ejmech.2024.116396_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003534","article-title":"Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis","volume":"9","author":"Bulman","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acsinfecdis.0c00546","article-title":"Antileishmanial chemotherapy through clemastine fumarate mediated inhibition of the leishmania inositol phosphorylceramide synthase","volume":"7","author":"Mina","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib36","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","article-title":"Repurposing strategies for tropical disease drug discovery","volume":"26","author":"Klug","year":"2016","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.116396_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000720","article-title":"NECT Is Next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness","volume":"4","author":"Yun","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116396_bib38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116396_bib39","article-title":"Disulfiram repurposing in the combined chemotherapy of Chagas disease: a protocol for phase I\/II clinical trial","volume":"2","author":"Saraiva","year":"2021","journal-title":"Med Case Rep Study Protoc"},{"key":"10.1016\/j.ejmech.2024.116396_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1233253","article-title":"Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities","volume":"14","author":"Porta","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116396_bib41","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2174\/1568026623666230201103843","article-title":"Structural insight into privileged heterocycles as anti-trypanosoma cruzi and brucei agents","volume":"23","author":"Abbasi Shiran","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib42","unstructured":"https:\/\/www.who.int\/health-topics\/chagas-disease (Accessed May, 2023)."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116396_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000345","article-title":"Modelling historical changes in the force-of-infection of Chagas disease to inform control and elimination programmes: application in Colombia","volume":"2","author":"Cucunub\u00e1","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ejmech.2024.116396_bib44","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.1021\/acsomega.2c03395","article-title":"Mitochondrial imbalance of trypanosoma cruzi Induced by the marine alkaloid 6-Bromo-2\u2032-de-N-methylaplysinopsin","volume":"7","author":"Romanelli","year":"2022","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116396_bib45","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/jm049002a","article-title":"Class II (IIa)- selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides","volume":"48","author":"Mai","year":"2005","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2024.116396_bib46","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1021\/jm034167p","article-title":"Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A","volume":"46","author":"Mai","year":"2003","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116396_bib47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/cmdc.201300005","article-title":"Tert-butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells","volume":"8","author":"Valente","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116396_bib48","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1021\/acsinfecdis.2c00232","article-title":"Effects of structurally different HDAC inhibitors against tyypanosoma cruzi, leishmania, and schistosoma mansoni","volume":"8","author":"Di Bello","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib49","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.9b01852","article-title":"Discovery and optimization of a compound series active against trypanosoma cruzi, the causative agent of chagas disease","volume":"63","author":"Harrison","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib50","first-page":"995","volume":"vol. 14","author":"Lara","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116396_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/acsmedchemlett.8b00498","article-title":"Triazolopyrimidines and imidazopyridines: structure-activity relationships and in vivo efficacy for trypanosomiasis","volume":"10","author":"Nagendar","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"7619","key":"10.1016\/j.ejmech.2024.116396_bib52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"50","key":"10.1016\/j.ejmech.2024.116396_bib53","doi-asserted-by":"crossref","first-page":"47225","DOI":"10.1021\/acsomega.2c06455","article-title":"Synthesis and antitrypanosomal and mechanistic studies of a series of 2-arylquinazolin-4-hydrazines: a hydrazine moiety as a selective, safe, and specific pharmacophore to design antitrypanosomal agents targeting NO release","volume":"7","author":"Romero","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116396_bib54","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.8b01464","article-title":"Design, synthesis, and biological evaluation of new 1-(aryl-1H-pyrrolyl)(phenyl)methyl-1H-imidazole derivatives as antiprotozoal agents","volume":"62","author":"Saccoliti","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116396_bib56","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1021\/jm301059b","article-title":"Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1","volume":"55","author":"Orrling","year":"2012","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib57","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1021\/acsomega.8b02847","article-title":"Phenyldihydropyrazolones as novel lead compounds against Trypanosoma cruzi","volume":"4","author":"Sijm","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116396_bib58","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acsmedchemlett.7b00202","article-title":"New cass of antitrypanosomal agents based on imidazopyridines","volume":"8","author":"Silva","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116396_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cmdc.202000616","article-title":"Synthesis and structure-activity relationships of imidazopyridine\/pyrimidine- and furopyridine-based antiinfective agents against trypanosomiasis","volume":"16","author":"Silva","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116396_bib60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acsinfecdis.7b00212","article-title":"Optimization of physicochemical properties for 4-anilinoquinoline inhibitors of plasmodium falciparum proliferation","volume":"4","author":"Mehta","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006834","article-title":"Anilinoquinoline based inhibitors of trypanosomatid proliferation","volume":"12","author":"Ferrins","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/acs.jmedchem.8b01365","article-title":"Improvement of aqueous solubility of lapatinib-derived analogs: identification of a quinolinimine as a lead for human african trypanosomiasis drug development","volume":"62","author":"Bachovchin","year":"2019","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116396_bib63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/acsmedchemlett.9b00453","article-title":"Scaffold and parasite hopping: discovery of new protozoal proliferation inhibitors","volume":"11","author":"Singh","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116396_bib64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pt.2017.12.002","article-title":"Fexinidazole: a new drug for African sleeping sickness on the horizon","volume":"34","author":"Pollastri","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2024.116396_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human african trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116396_bib66","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis: pharmacological re-engagement with a neglected disease","volume":"152","author":"Barrett","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116396_bib67","first-page":"93","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"Franco","year":"2012","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.ejmech.2024.116396_bib68","first-page":"1","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"39","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116396_bib69","doi-asserted-by":"crossref","first-page":"e999","DOI":"10.1016\/S2214-109X(21)00208-4","article-title":"Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study","volume":"9","author":"Kande","year":"2021","journal-title":"Lancet Global Health"},{"issue":"38","key":"10.1016\/j.ejmech.2024.116396_bib70","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF3","volume":"115","author":"Wall","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116396_bib71","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1021\/acs.jmedchem.6b00442","article-title":"Hit-to-lead optimization of a novel class of potent, broad-spectrum trypanosomacides","volume":"59","author":"Russell","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2024.116396_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214470","article-title":"Drug combination studies of the dipeptide nitrile CD24 with curcumin: a new strategy to synergistically inhibit rhodesain of trypanosoma brucei rhodesiense","volume":"23","author":"Di Chio","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116396_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112043","article-title":"Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency","volume":"189","author":"Franco","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejmech.2012.04.029","article-title":"Discovery of a new antileishmanial hit in 8-nitroquinoline series","volume":"54","author":"Paloque","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib75","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1021\/acsmedchemlett.9b00566","article-title":"New 8-nitroquinolinone derivative displaying submicromolar in vitro activities against both trypanosoma brucei and cruzi","volume":"11","author":"Pedron","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116396_bib76","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1021\/acs.jmedchem.2c00232","article-title":"Multitarget, selective compound design yields potent inhibitors of a kinetoplastid pteridine reductase 1","volume":"65","author":"P\u00f6hner","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib77","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejmech.2019.04.052","article-title":"Thiazolidinone\/thiazole based hybrids - new class of antitrypanosomal agents","volume":"174","author":"Kryshchyshyn","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116396_bib78","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/open.202100180","article-title":"Development of novel isoindolone-based compounds against Trypanosoma brucei rhodesiense","volume":"10","author":"Silva","year":"2021","journal-title":"Chemist"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib79","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/acs.jmedchem.9b01741","article-title":"Selectivity and physicochemical optimization of repurposed pyrazolo[1,5-b]pyridazines for the treatment of human african trypanosomiasis","volume":"63","author":"Tear","year":"2020","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116396_bib80","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/cmdc.201300072","article-title":"From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules","volume":"8","author":"Woodland","year":"2013","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116396_bib81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsmedchemlett.9b00218","article-title":"Discovery of potent N-ethylurea pyrazole derivatives as dual inhibitors of trypanosoma brucei and trypanosoma cruzi","volume":"11","author":"Varghese","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116396_bib82","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Treatment options for leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejmech.2024.116396_bib83","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.trstmh.2006.03.009","article-title":"Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives","volume":"100","author":"Croft","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116396_bib84","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0035-9203(03)80043-3","article-title":"Sodium stibogluconate cardiotoxicity and safety of generics","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans. R. Soc. Trop. Med. Hyg. T ROY SOC TROP MED H."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2024.116396_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8629039","article-title":"Efficacy and safety of paromomycin for visceral leishmaniasis: a systematic review","volume":"2021","author":"Pokharel","year":"2021","journal-title":"J. Trop. Med."},{"key":"10.1016\/j.ejmech.2024.116396_bib87","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.parint.2016.06.009","article-title":"Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection","volume":"65","author":"Faucher","year":"2016","journal-title":"Parasitol. Int."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib88","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acs.jchemed.1c01213","article-title":"Open synthesis network research in an undergraduate laboratory: development of benzoxazole amide derivatives against leishmania parasite","volume":"99","author":"Faville","year":"2022","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.ejmech.2024.116396_bib89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.8b00347","article-title":"Nongenotoxic 3-nitroimidazo[1,2-a]pyridines are NTR1 substrates that display potent in vitro antileishmanial activity","volume":"10","author":"Fersing","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116396_bib90","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116396_bib91","doi-asserted-by":"crossref","first-page":"13140","DOI":"10.1021\/acs.jmedchem.0c01589","article-title":"Evaluation of the pharmacophoric role of the O\u2212O bond in synthetic antileishmanial compounds: comparison between 1,2-dioxanes and tetrahydropyrans","volume":"63","author":"Ortalli","year":"2020","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116396_bib92","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1021\/acs.jcim.2c00731","article-title":"Prediction of antileishmanial compounds: general model, preparation, and evaluation of 2-acylpyrrole derivatives","volume":"62","author":"Santiago","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116396_bib93","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/acs.jmedchem.9b00628","article-title":"Synthesis, biological evaluation, structure-activity relationship, and mechanism of action studies of quinoline-metronidazole derivatives against experimental visceral leishmaniasis","volume":"62","author":"Upadhyay","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib94","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s11030-022-10508-3","article-title":"Synthesis, antileishmanial activity and molecular modeling of new 1-aryl\/alkyl-3-benzoyl\/cyclopropanoyl thiourea derivatives","volume":"27","author":"Mohammadi-Ghalehbin","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2024.116396_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127616","article-title":"Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds","volume":"30","author":"Schadich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116396_bib96","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bmcl.2009.01.083","article-title":"First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness","volume":"19","author":"Smith","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib97","first-page":"95","article-title":"Synthesis and comparison of in vitro leishmanicidal activity of 5-(nitroheteroaryl)-1,3,4-thiadiazols containing cyclic amine of piperidine-4-ol at C-2 with acyclic amine analogues against Iranian strain of leishmania major (MRHO\/IR\/75\/ER)","volume":"11","author":"Tahghighi","year":"2017","journal-title":"J Arthropod-Borne Dis"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib98","first-page":"1816","article-title":"Novel 5-(nitrothiophene-2-yl)-1, 4-thiadiazole derivatives: synthesis and antileishmanial activity against promastigote stage of leishmania major","volume":"18","author":"Sadat-Ebrahimi","year":"2019","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"key":"10.1016\/j.ejmech.2024.116396_bib99","doi-asserted-by":"crossref","DOI":"10.1039\/D0RA07881F","article-title":"Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues","volume":"10","author":"Nandikolla","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2024.116396_bib100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cbdd.14097","article-title":"Exploring novel nitrofuranyl sulfonohydrazides as anti-Leishmania and anti-cancer agents: synthesis, in vitro efficacy and hit identification","volume":"100","author":"Kannigadu","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2024.116396_bib101","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/acsmedchemlett.1c00354","article-title":"Development of potent 3-Br-isoxazoline-based antimalarial and antileishmanial compounds","volume":"12","author":"Galbiati","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116396_bib102","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1021\/acs.jmedchem.8b02021","article-title":"Enhancement of benzothiazoles as pteridine reductase-1 inhibitors for the treatment of trypanosomatidic infections","volume":"62","author":"Linciano","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104437","article-title":"Antileishmanial effects of 4-phenyl-1-[2-(phthalimido-2-yl)ethyl]-1H-1,2,3-triazole (PT4) derivative on Leishmania amazonensis and Leishmania braziliensis: in silico ADMET, in vitro activity, docking and molecular dynamic simulations","volume":"105","author":"Holanda","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib104","doi-asserted-by":"crossref","first-page":"13807","DOI":"10.1039\/D0NJ01206H","article-title":"Optimization of phthalazin-based aryl\/heteroarylhydrazones to design new promising antileishmanicidal agents: synthesis and biological evaluation of 3-aryl-6-piperazin-1,2,4-triazolo[3,4-a]phthalazines","volume":"44","author":"Romero","year":"2020","journal-title":"New J. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11030-016-9693-8","article-title":"Synthesis of new quinazolin-2,4-diones as anti-Leishmania mexicana agents","volume":"20","author":"Enciso","year":"2016","journal-title":"Mol. Divers."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116396_bib106","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1021\/acs.jmedchem.1c00813","article-title":"Amino-substituted 3-aryl- and 3-heteroarylquinolines as potential antileishmanial agents","volume":"64","author":"Hammill","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.725892","article-title":"Benzopyrazine-based small molecule inhibitors as trypanocidal and leishmanicidal agents: green synthesis, in vitro, and in silico evaluations","volume":"9","author":"Rock","year":"2021","journal-title":"Front. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116396_bib108","article-title":"Targeting tRNA-synthetase interactions towards novel therapeutic discovery against eukaryotic pathogens","volume":"2020","author":"Kelly","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116396_bib109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573406417666210216154428","article-title":"Synthesis, antileishmanial activity and in silico studies of aminoguanidine hydrazones (AGH) and thiosemicarbazones (TSC) against leishmania chagasi amastigotes","volume":"18","author":"de Aquino","year":"2022","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib110","first-page":"345","article-title":"Visceral leishmaniasis - current therapeutic modalities","volume":"123","author":"Sundar","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2024.116396_bib111","first-page":"355","article-title":"Invasive amoebiasis: a review of Entamoeba infections highlighted with case reports","volume":"28","author":"Skappak","year":"2014","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116396_bib112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.11150\/kansenshogakuzasshi.86.773","article-title":"Amebic colitis and liver abscess complicated by high serum procalcitonin in acute myeloid leukemia","volume":"86","author":"Oku","year":"2012","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.ejmech.2024.116396_bib113","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy161","article-title":"A review of the global burden, new diagnostics, and current therapeutics for amebiasis","volume":"5","author":"Shirley","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.116396_bib114","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.3390\/app11125742","article-title":"Synthetic transformations and medicinal significance of 1,2,3-thiadiazoles derivatives: an update","volume":"11","author":"Irfan","year":"2021","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12272-015-0686-4","article-title":"Novel aryl carbamate derivatives of metronidazole as potential antiamoebic agents","volume":"39","author":"Hayat","year":"2016","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116396_bib116","first-page":"1183","article-title":"Antiamoebic activity of imidazothiazole derivatives against opportunistic pathogen Acanthamoeba castellanii","volume":"11","author":"Akbar","year":"2022","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2024.116396_bib117","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.5012\/bkcs.2010.31.10.2854","article-title":"Synthesis of new 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo [2,1-b]thiazole derivatives and their antiproliferative activity against melanoma cell line","volume":"31","author":"Park","year":"2010","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116396_bib118","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.ejmech.2011.08.024","article-title":"New imidazo [2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation and in silico studies","volume":"46","author":"Park","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib119","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00044-016-1529-7","article-title":"Broad-spectrum antiproliferative activity of a series of 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo [2,1-b]thiazole derivatives","volume":"25","author":"Abdel-Maksoud","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.116396_bib120","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1080\/14756366.2020.1819260","article-title":"Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies","volume":"35","author":"Anbar","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib121","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1021\/acs.jmedchem.1c00230","article-title":"Discovery of new imidazo [2,1-b]thiazole derivatives as potent Pan-RAF inhibitors with promising in vitro and in vivo anti-melanoma activity","volume":"64","author":"Abdel-Maksoud","year":"2021","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2024.116396_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127549","article-title":"Synthesis of metronidazole based thiazolidinone analogs as promising antiamoebic agents","volume":"30","author":"Ansari","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116396_bib123","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2016.08.053","article-title":"Synthesis, antiamoebic and molecular docking studies of furan-thiazolidinone hybrids","volume":"124","author":"Ansari","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib124","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.bmc.2013.12.069","article-title":"Synthesis of 3-tetrazolylmethyl-4H-chromen-4-ones via Ugi-azide and biological evaluation against Entamoeba histolytica, Giardia lamblia and Trichomona vaginalis","volume":"22","author":"Cano","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116396_bib125","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.3390\/molecules200712436","article-title":"In Vitro studies of chromone-tetrazoles against pathogenic protozoa, bacteria, and fungi","volume":"20","author":"Cano","year":"2015","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116396_bib126","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1021\/acsomega.8b00170","article-title":"Solvent- and catalyst-free one-pot green bound-type fused bis-heterocycles synthesis via Groebke-Blackburn-Bienaym\u00e9 reaction\/SNAr\/ring-chain azido-tautomerization strategy","volume":"3","author":"Claudio-Catal\u00e1n","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116396_bib127","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1872213X13666190618124901","article-title":"Giardiasis: an overview","volume":"13","author":"Leung","year":"2019","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116396_bib128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.rvsc.2020.09.034","article-title":"Giardia duodenalis in humans and animals - transmission and disease","volume":"135","author":"Dixon","year":"2021","journal-title":"Res. Vet. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116396_bib129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pt.2006.02.015","article-title":"Giardia and cryptosporidium join the 'neglected diseases initiative'","volume":"22","author":"Savioli","year":"2006","journal-title":"Trends Parasitol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116396_bib130","first-page":"336","article-title":"Giardiasis: report of a case refractory to treatment","volume":"27","author":"Iza","year":"2019","journal-title":"Inf. Med."},{"key":"10.1016\/j.ejmech.2024.116396_bib131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.actatropica.2015.09.023","article-title":"A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children","volume":"153","author":"Escobedo","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2024.116396_bib132","doi-asserted-by":"crossref","DOI":"10.1155\/2007\/21261","article-title":"Survey of obstetrician-gynecologists about giardiasis","volume":"2007","author":"Krueger","year":"2007","journal-title":"Infect. Dis. Obstet. Gynecol."},{"issue":"24","key":"10.1016\/j.ejmech.2024.116396_bib133","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.3390\/molecules27248902","article-title":"Pyridyl methylsulfinyl benzimidazole derivatives as promising agents against Giardia lamblia and trichomonas vaginalis","volume":"27","author":"Hern\u00e1ndez-Ochoa","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116396_bib134","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15789\/2220-7619-PAO-2024","article-title":"Pharmaceutical activity of a synthetic heterocyclic (C15H12N5OCl) compound on Ntamoeba histolyca and Giardia lamblia","volume":"13","author":"Obaid","year":"2023","journal-title":"Russ. J. Infect. Immun"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116396_bib135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/molecules25040793","article-title":"Metronidazole and secnidazole carbamates: synthesis, antiprotozoal activity, and molecular dynamics studies","volume":"25","author":"Rocha-Gardu\u00f1o","year":"2020","journal-title":"Molecules"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:33:19Z","timestamp":1717234399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":135,"alternative-id":["S0223523424002769"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116396","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116396"}}